Prevalence of bacterial vaginosis in Portuguese pregnant women and vaginal colonization by *Gardnerella vaginalis*

Daniela Machado 1, Joana Castro 1, 2, José Martinez-de-Oliveira 3, 4, Cristina Nogueira-Silva 5, 6, 7, Nuno Cerca Corresp. 1

1 Centre of Biological Engineering (CEB), Laboratory of Research in Biofilms Rosário Oliveira (LIBRO), University of Minho, Braga, Portugal
2 Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
3 Women & Child Health Department, Centro Hospitalar Cova da Beira EPE, Covilhã, Portugal
4 CICS-UBI, Health Sciences Research Center, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal
5 Department of Obstetrics and Gynecology, Hospital de Braga, Braga, Portugal
6 Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga, Portugal
7 ICVS/3B’s, Braga/Guimarães, Portugal

Corresponding Author: Nuno Cerca
Email address: nunocerca@ceb.uminho.pt

**Background.** We aimed to determine the prevalence of vaginal colonization by *Gardnerella vaginalis* and of bacterial vaginosis (BV) in Portuguese pregnant women, and to identify risk factors for BV and *G. vaginalis* colonization in pregnancy. **Methods.** A cross-sectional study was conducted among pregnant women aged ≥18 years who were attending in two public hospitals of the Northwest region of Portugal. Epidemiological data was collected by anonymous questionnaire. BV was diagnosed by Nugent criteria and *G. vaginalis* presence was identified by polymerase chain reaction. Crude associations between the study variables and BV or *G. vaginalis* colonization were quantified by odds ratios (ORs) and their 95% confidence intervals (CIs). **Results.** The prevalences of BV and of *G. vaginalis* colonization among Portuguese pregnant women were 3.88% and 67.48%, respectively. Previous preterm delivery and colonization by *G. vaginalis* were factors with very high OR, but only statistically significant for a 90% CI. Conversely, higher rates of *G. vaginalis* colonization were found in women with basic educational level (OR = 2.77, 95% CI [1.33-5.78]), during the second trimester of pregnancy (OR = 6.12, 95% CI [1.80-20.85]) and with BV flora (OR = 8.73, 95% CI [0.50-153.60]). **Discussion.** Despite the lower number of women with BV, prevalence ratios and association with risk factors were similar to recent European studies. However, the percentage of healthy women colonized by *G. vaginalis* was significantly higher than many previous studies, confirming that *G. vaginalis* colonization does not always lead to BV development.
Prevalence of bacterial vaginosis in Portuguese pregnant women and vaginal colonization by *Gardnerella vaginalis*

Daniela Machado¹, Joana Castro¹,², José Martinez-de-Oliveira³,⁴ Cristina Nogueira-Silva⁵,⁶,⁷ and Nuno Cerca¹

¹Centre of Biological Engineering (CEB), Laboratory of Research in Biofilms Rosário Oliveira (LIBRO), University of Minho, Braga, Portugal
²Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, Portugal
³CICS-UBI, Health Sciences Research Center, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal
⁴Women & Child Health Department, Centro Hospitalar Cova da Beira EPE, Covilhã, Portugal
⁵Department of Obstetrics and Gynecology, Hospital de Braga, Braga, Portugal
⁶Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga, Portugal
⁷ICVS/3B’s, Braga / Guimarães, Portugal

**Corresponding author:**

Nuno Cerca¹

E-mail address: nunocerca@ceb.uminho.pt
ABSTRACT

Background. We aimed to determine the prevalence of vaginal colonization by *Gardnerella vaginalis* and of bacterial vaginosis (BV) in Portuguese pregnant women, and to identify risk factors for BV and *G. vaginalis* colonization in pregnancy.

Methods. A cross-sectional study was conducted among pregnant women aged ≥18 years who were attending in two public hospitals of the Northwest region of Portugal. Epidemiological data was collected by anonymous questionnaire. BV was diagnosed by Nugent criteria and *G. vaginalis* presence was identified by polymerase chain reaction. Crude associations between the study variables and BV or *G. vaginalis* colonization were quantified by odds ratios (ORs) and their 95% confidence intervals (CIs).

Results. The prevalences of BV and of *G. vaginalis* colonization among Portuguese pregnant women were 3.88% and 67.48%, respectively. Previous preterm delivery and colonization by *G. vaginalis* were factors with very high OR, but only statistically significant for a 90% CI. Conversely, higher rates of *G. vaginalis* colonization were found in women with basic educational level (OR = 2.77, 95% CI [1.33-5.78]), during the second trimester of pregnancy (OR = 6.12, 95% CI [1.80-20.85]) and with BV flora (OR = 8.73, 95% CI [0.50-153.60]).

Discussion. Despite the lower number of women with BV, prevalence ratios and association with risk factors were similar to recent European studies. However, the percentage of healthy women colonized by *G. vaginalis* was significantly higher than many previous studies, confirming that *G. vaginalis* colonization does not always lead to BV development.
INTRODUCTION

Worldwide, bacterial vaginosis (BV) is considered to be one of the most prevalent gynecological disorders of reproductive-age women and one of the most common causes of vaginal symptoms, prompting women to seek medical care (Sobel, 1997). This vaginal infection is microbiologically characterized by the replacement of a *Lactobacillus*-dominated vaginal microbiota by variable mixtures of strictly and facultative anaerobic bacteria including *Gardnerella vaginalis*, *Atopobium vaginae* and *Mobiluncus* spp. (Verhelst et al., 2004).

Currently, the presence of BV during pregnancy has attracted the attention of both clinicians and the scientific community, due to its relation with adverse pregnancy consequences such as preterm delivery (Leitch et al., 2003) and miscarriage (Leitch & Kiss, 2007). The mechanisms involved in pregnancy complications induced by BV are not fully clarified, but many researchers suggest that preterm delivery results from bacteria ascension from vagina to the membranes and amniotic fluid (Goldenberg, Hauth & Andrews, 2000; Pararas, Skevaki & Kafetzis, 2006). In recent years, several studies demonstrated that the presence or high load of vaginal microbes associated to BV such as *G. vaginalis*, *A. vaginae*, *Mobiluncus* spp., *Mycoplasma* spp. and *Leptotrichia/Sneathia* species, were related with an increased risk of preterm birth (Foxman et al., 2014; Nelson et al., 2014; Bretelle et al., 2015; Kuon et al., 2017). However, the great diversity of vaginal microbiota in women with BV affects its potential to develop preterm birth and other negative outcomes in pregnancy (Hyman et al., 2014; Nelson et al., 2015) and it becomes BV treatment in pregnant women a challenging task (Haahr et al., 2016). Despite of its high impact, few epidemiological studies on BV have been conducted in Portugal (Guerreiro, Gigante & Teles, 1998; Silva et al., 2014; Machado et al., 2015). Specifically, there is no information related to the prevalence of BV among Portuguese pregnant women. As such, we set this first epidemiological study aimed to determine the prevalences of BV and of *G. vaginalis* vaginal colonization in Portuguese pregnant women.

MATERIALS & METHODS

Population, data and biological samples collection

This cross-sectional study involved pregnant women attending prenatal care consultations in two public Portuguese hospitals of the Northwest region (Hospital of Braga and Unidade Local de Saúde de Matosinhos), between May 2014 and May 2016. The inclusion criteria for the present
study were: to be pregnant at any gestational age and to be older than 18 years. The exclusion criteria were: women who were unable to read or understand Portuguese and who did not accept to participate in study.

During prenatal care consultation, obstetricians invited all eligible women under their care to participate in the study. All participants signed the informed consent form, as approved by the respective local ethical committees. Afterwards, the participants were questioned by the obstetricians about their age, educational level (basic, secondary or university), if they had previous BV episodes, previous deliveries, history of preterm delivery, suffered of chronic disease or smoking and about its use of intimate hygienic products and vitamin supplements, and determined the current gestational period (first, second or third trimester). A short standardized questionnaire was used to collect these data. Finally, the obstetricians collected vaginal samples (only one sample point was taken for each participant), using sterile swab containing Amies transport medium with coal (VWR, Radnor, PA, USA). After collection, the swabs were immediately conserved at 4ºC and transported to the Laboratory of Research in Biofilms Rosário Oliveira of the University of Minho, where they were processed.

**Gram staining and BV diagnosis**

For BV diagnosis, a direct smear was performed by transferring the vaginal fluid present on the swab to a glass slide. Then vaginal smears were heat-fixed and Gram stained (Spiegel, Amsel & Holmes, 1983). Afterwards, the smears were visualized using an Olympus BX51 microscope (Olympus Portugal SA, Lisboa, Portugal) under oil immersion objective (1000× magnification) and, subsequently, graded in accordance with the Nugent scoring system (Nugent, Krohn & Hillier, 1991). In summary, on 10 microscopic fields, the following bacterial morphotypes were identified and quantified: large gram-positive rods (*Lactobacillus* spp.), small gram-variable rods (*G. vaginalis*), small gram-negative rods (*Bacteroides* spp.) and curved gram-variable rods (*Mobiluncus* spp.). The sum of each morphotype score allowed to classify vaginal flora into normal (score 0-3), intermediate (score 4-6) or BV (score 7-10).

**Molecular detection of *G. vaginalis***

Each vaginal swab was then immersed in 2 mL of 0.9% (wt/v) of sodium chloride (Liofilchem, Roseto degli Abruzzi, Italy) and the content was suspended using vigorous vortexing. Afterwards, 1.5 mL of each diluted swab content was transferred into a tube that was centrifuged at 8000 rpm, during 10 seconds, in order to allow for coal deposition at the bottom of the tube.
Then, 0.6 mL of supernatant was collected to a new tube and this later was centrifuged at 13500 rpm, during 5 minutes. At the end, the supernatant was discarded and the pellet was suspended in 0.1 mL of sterile ultra-pure water. This bacterial suspension was incubated in a heating block at 95°C for 20 minutes in order to disrupt bacterial cell wall and release the cell content, making available the genomic DNA that is required for polymerase chain reaction (PCR). After incubation, it was immediately cooled on ice for 5 minutes and the cell suspension was centrifuged at 13500 rpm, during 5 minutes. The supernatant was used as template for a multiplex PCR since we used the PCR to amplify different DNA sequences simultaneously (namely gene encoding 16S rRNA of *G. vaginalis* and *aap* gene of *Staphylococcus epidermidis*).

Briefly, each PCR included 6 µL of Dream Taq PCR Master Mix 2X (Thermo Fisher Scientific, Waltham, MA, USA), 1 µL of DNA from the vaginal sample, 2 µL of distilled water DNase/RNAse free (Thermo Fisher Scientific), 0.5 µL of 5 µM forward (FW1) *G. vaginalis* primer, 0.5 µL of 5 µM reverse (RV1) *G. vaginalis* primer, 0.5 µL of 5 µM FW *S. epidermidis* primer, 0.5 µL of 5 µM RV *S. epidermidis* primer and 1 µL of complementary DNA of *S. epidermidis*. Also, a negative control (containing 1 µL of DNase/RNase free water instead of genomic DNA) and positive control (containing 1 µL of genomic DNA from pure culture of *G. vaginalis*) were included in each set of reactions. The tubes were placed in a thermocycler (Bio-Rad, Hercules, CA, USA) that was programmed with the following protocol: 94°C for 2 minutes, 40 steps of 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 1 minute and finally 72°C for 5 minutes. The inclusion of the specific primers for the *S. epidermidis aap* gene acted as internal positive control of PCR procedure, in order to ensure that amplifiable DNA was successfully extracted and there are no PCR inhibitors on sample.

After the PCR reaction, amplified products were analyzed in 1% (wt/v) of agarose (SeaKem® LE, Rockland, ME, USA) gel with 0.05 µL/mL midori green nucleic acid dye (Nippon Genetics Europe GmbH, Düren, Germany). The electrophoresis run for 50 minutes at 100 volts. Finally, the results were visualized using the ChemiDoc (Bio-Rad) system, according to the manufacturer's instructions. Negative results for the amplification of the gene encoding 16S rRNA of *G. vaginalis* were confirmed using an independent set of primers (FW2/RV2). All primers used are described in Table 1 and were previously assessed for specificity (França et al., 2012; Henriques et al., 2012; Castro et al., 2017).
Data were analyzed with GraphPad Prism version 6 (GraphPad Software Inc, La Jolla, CA, USA). Firstly, we determined BV and *G. vaginalis* colonization prevalences and then we used Chi-square or Fisher’s exact test to verify whether BV positive status or *G. vaginalis* colonization were associated with some sociodemographic, medical, reproductive, behavioral or microbiological variables. A $p$-value<$0.05$ was used as threshold for statistically significance. The strength of association between BV diagnosis or *G. vaginalis* colonization with the study variables was assessed through calculation of odds ratios (OR) and their 95% confidence intervals (CI).

**Ethical considerations**

The study was approved by the ethics committees of Unidade Local de Saúde de Matosinhos (process 013/CE/JAS) and of Hospital of Braga (process SECVS 063/2014). All the study participants agreed through informed consent to collaborate voluntarily, anonymously and freely. To ensure confidentiality no personal data were recorded that could lead to identification of the participants.

**RESULTS**

Between May 2014 and May 2016, a total of 273 women followed in prenatal care consultation of two public Portuguese hospitals of the Northwest region agreed to participate in the current study. Among them, 67 had uninterpretable Gram-staining slides and were excluded from this study. Table 2 summarizes sociodemographic, medical, reproductive and behavioral characteristics of the studied population ($n = 206$). The participants had ages comprised between 19 and 41 years-old, resulting in mean age of 30.00 ± 5.16 years. Moreover, the majority of participants was in the third trimester of pregnancy (71.84%) and used vitamin supplementation (86.41%).

Among the 206 pregnant women, BV was diagnosed in only 8 participants, resulting in a BV prevalence of 3.88% (Table 3). Probably due to the low number of BV cases, we did not found any significant statistically association between BV and the risk factors considered in this study ($p$-value>$0.05$). Nevertheless, previous preterm delivery and colonization by *G. vaginalis* were factors with very high OR, that could be considered statistically significant for a 90% CI.
Vaginal colonization by *G. vaginalis* was detected in 139 samples, representing a prevalence rate of 67.48% (Table 4). Statistically significant differences between *G. vaginalis* positive and negative groups were found in relation to maternal educational level, current pregnancy trimester and vaginal microflora profile (p value <0.05). Of note that, basic educational level (OR = 2.77, 95% CI [1.33-5.78]), second pregnancy trimester (OR = 6.12, 95% CI [1.80-20.85]) and presence of BV flora (OR = 8.73, 95% CI [0.50-153.60]) were associated with higher rates of *G. vaginalis* colonization in these pregnant women.

**DISCUSSION**

This is the first epidemiological study conducted in Portugal with the aim to assess the prevalence of BV among pregnant women, as well as to identify risk factors for BV and *G. vaginalis* colonization during pregnancy. In contrast with the high frequency of *G. vaginalis*, BV was diagnosed in only 3.88% of studied population. This BV prevalence rate is much lower than that reported by other Portuguese studies (Guerreiro, Gigante & Teles, 1998; Machado et al., 2015). Indeed, Guerreiro et al. detected a BV prevalence of 7% among 840 contraceptive users living in Lisbon region (Guerreiro, Gigante & Teles, 1998) while Machado et al. found a BV rate of 17.33%, among 150 young Portuguese women (Machado et al., 2015). Despite the lower cases of pregnant women with BV reported in this study, our results were consistent with other European studies. Cristiano et al. described a BV prevalence rate of 4.9% in 1441 Italian pregnant women (Cristiano et al., 1996) while Gratacós and co-workers found BV in 4.5% among 492 Spanish women with low risk pregnancies (Gratacós et al., 1999). Akinbiyi and colleagues conducted a randomized prospective study to determine the prevalence and age distribution of *Candida albicans* and BV among English pregnant women, and found a BV prevalence of 3.54% (38/1073) with the majority of BV cases belonging to the age group of 21–30 years (Akinbiyi, Watson & Feyi-Waboso, 2008).

Contrasting with the very low prevalence of BV, in our study population, we found a *G. vaginalis* colonization rate of 67.48%. A significant higher colonization by *G. vaginalis* not associated to BV has been reported elsewhere (Cox et al., 2016; Janulaitiene et al., 2017). However, other epidemiological studies reported *G. vaginalis* colonization rates much lower than ours (Pépin et al., 2011; Schwebke, Flynn & Rivers, 2014; Silva et al., 2014). These differences might be the result of significant different populations at study. In fact, recent genomic studies...
described that vaginal microbiome in pregnancy is unique and distinct of the non-pregnant women (Aagaard et al., 2012; Jespers et al., 2015).

The observation that *G. vaginalis* colonization is not sufficient to cause BV, is not new (Aroutcheva et al., 2001; Fredricks et al., 2007; Menard et al., 2008). However, recent genomic studies have highlighted that *G. vaginalis* found in healthy women have distinct genetic profiles than isolates from women with BV (Schellenberg et al., 2016; Janulaitiene et al., 2017). Interestingly, it has been proposed that some of the known *G. vaginalis* genotypes are, in fact, distinct species (Cerca et al., 2017). This is supported by full genome sequence analysis and microbiology functional studies (Harwich et al., 2010; Yeoman et al., 2010; Castro et al., 2015).

**CONCLUSIONS**

For the first time, BV and *G. vaginalis* prevalence among Portuguese pregnant women were determined. We found that BV prevalence was low but *G. vaginalis* colonization was very high. Importantly, due to the small sample size, associations between BV and potential risk factors should be made with caution and as such, further studies involving a large number of participants and in different regions of the country should be performed in the future, to confirm our observations.

**ACKNOWLEDGMENTS**

We would like to thank the medical doctors of the Obstetrics and Gynecology of Hospital of Braga and Unidade Local de Saúde de Matosinhos, namely: Joana Barros, Bárbara Ribeiro, Catarina Peixinho, Catarina Vieira, Joana Félix, Leonor Bivar, Luís Braga, for technical support in collection of vaginal samples.

**REFERENCES**

Aagaard K., Riehle K., Ma J., Segata N., Mistretta TA., Coarfa C., Raza S., Rosenbaum S., Van den Veyver I., Milosavljevic A., Gevers D., Huttenhower C., Petrosino J., Versalovic J. 2012. A metagenomic approach to characterization of the vaginal microbiome signature in pregnancy. *PLoS One* 7:e36466. DOI: 10.1371/journal.pone.0036466.

Akinbiyi AA., Watson R., Feyi-Waboso P. 2008. Prevalence of *Candida albicans* and bacterial vaginosis in asymptomatic pregnant women in South Yorkshire, United Kingdom: Outcome
of a prospective study. *Archives of Gynecology and Obstetrics* 278:463–466. DOI: 10.1007/s00404-008-0593-8.

Aroutcheva AA., Simoes JA., Behbakht K., Faro S. 2001. *Gardnerella vaginalis* isolated from patients with bacterial vaginosis and from patients with healthy vaginal ecosystems. *Clinical Infectious Diseases* 33:1022–1027. DOI: 10.1086/323030.

Bretelle F., Rozenberg P., Pascal A., Favre R., Bohec C., Loundou A., Senat MV., Aissi G., Lesavre N., Brunet J., Heckenroth H., Luton D., Raoult D., Fenollar F., Groupe de Recherche en Obstetrique Gynecologie. 2015. High *Atopobium vaginae* and *Gardnerella vaginalis* vaginal loads are associated with preterm birth. *Clinical Infectious Diseases* 60:860–867. DOI: 10.1093/cid/ciu966.

Castro J., Alves P., Sousa C., Cereija T., França Â., Jefferson KK., Cerca N. 2015. Using an in-vitro biofilm model to assess the virulence potential of bacterial vaginosis or non-bacterial vaginosis *Gardnerella vaginalis* isolates. *Scientific Reports* 5:11640. DOI: 10.1038/srep11640.

Castro J., França A., Bradwell KR., Serrano MG., Jefferson KK., Cerca N. 2017. Comparative transcriptomic analysis of *Gardnerella vaginalis* biofilms vs. planktonic cultures using RNA-seq. *npj Biofilms and Microbiomes* 3:3. DOI: 10.1038/s41522-017-0012-7.

Cerca N., Vaneechoutte M., Guschin A., Swidsinski A. 2017. Polymicrobial infections and biofilms in women’s health Gahro Expert Group Meeting Report 2017. *Research in Microbiology* pii: S0923-2508(17)30129-8. DOI: 10.1016/j.resmic.2017.07.002.

Cox C., Watt AP., McKenna JP., Coyle PV. 2016. *Mycoplasma hominis* and *Gardnerella vaginalis* display a significant synergistic relationship in bacterial vaginosis. *European Journal of Clinical Microbiology and Infectious Diseases* 35:481–487. DOI: 10.1007/s10096-015-2564-x.

Cristiano L., Rampello S., Noris C., Valota V. 1996. Bacterial vaginosis: prevalence in an Italian population of asymptomatic pregnant women and diagnostic aspects. *European Journal of Epidemiology* 12:383–390.

Foxman B., Wen A., Srinivasan U., Goldberg D., Marrs CF., Owen J., Wing DA., Misra D. 2014. *Mycoplasma*, bacterial vaginosis-associated bacteria BVAB3, race, and risk of preterm birth in a high-risk cohort. *American Journal of Obstetrics and Gynecology* 210:226.e1–7. DOI: 10.1016/j.ajog.2013.10.003.
França A., Freitas AI., Henriques AF., Cerca N. 2012. Optimizing a qPCR gene expression quantification assay for *S. epidermidis* biofilms: a comparison between commercial kits and a customized protocol. *PLoS One* 7:e37480. DOI: 10.1371/journal.pone.0037480.

Fredricks DN., Fiedler TL., Thomas KK., Oakley BB., Marrazzo JM. 2007. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. *Journal of Clinical Microbiology* 45:3270–3276. DOI: 10.1128/JCM.01272-07.

Goldenberg RL., Hauth JC., Andrews WW. 2000. Intrauterine infection and preterm delivery. *The New England Journal of Medicine* 342:1500–1507. DOI: 10.1056/NEJM200005183422007.

Gratacós E., Figueras F., Barranco M., Ros R., Andreu A., Alonso PL., Cararach V. 1999. Prevalence of bacterial vaginosis and correlation of clinical to Gram stain diagnostic criteria in low risk pregnant women. *European Journal of Epidemiology* 15:913–916.

Guerreiro D., Gigante MA., Teles LC. 1998. Sexually transmitted diseases and reproductive tract infections among contraceptive users. *International Journal of Gynaecology and Obstetrics* 63:S167-173.

Haahr T., Ersbøll AS., Karlsen MA., Svare J., Sneider K., Hee L., Weile LK., Ziobrowska-Bech A., Østergaard C., Jensen JS., Helmig RB., Uldbjerg N. 2016. Treatment of bacterial vaginosis in pregnancy in order to reduce the risk of spontaneous preterm delivery – a clinical recommendatio. *Acta Obstetricia et Gynecologica Scandinavica* 95:850–860. DOI: 10.1111/aogs.12933.

Harwich MD., Alves JM., Buck GA., Strauss JF., Patterson JL., Oki AT., Girerd PH., Jefferson KK. 2010. Drawing the line between commensal and pathogenic *Gardnerella vaginalis* through genome analysis and virulence studies. *BMC Genomics* 11:375. DOI: 10.1186/1471-2164-11-375.

Henriques A., Cereija T., Machado A., Cerca N. 2012. *In silico vs in vitro* analysis of primer specificity for the detection of *Gardnerella vaginalis*, *Atopobium vaginae* and *Lactobacillus* spp. *BMC Research Notes* 5:637. DOI: 10.1186/1756-0500-5-637.

Hyman RW., Fukushima M., Jiang H., Fung E., Rand L., Johnson B., Vo KC., Caughey AB., Hilton JF., Davis RW., Giudice LC. 2014. Diversity of the vaginal microbiome correlates with preterm birth. *Reproductive Sciences* 21:32–40. DOI: 10.1177/1933719113488838.

Janulaitiene M., Paliulyte V., Grinceviciene S., Zakareviciene J., Vladisauskiene A., Marcinkute
A., Pleckaityte M. 2017. Prevalence and distribution of *Gardnerella vaginalis* subgroups in women with and without bacterial vaginosis. *BMC Infectious Diseases* 17:394. DOI: 10.1186/s12879-017-2501-y.

Jespers V., van de Wijgert J., Cools P., Verhelst R., Verstraelen H., Delany-Moretlwe S., Mwaura M., Ndayisaba GF., Mandaliya K., Menten J., Hardy L., Crucitti T., Vaginal Biomarkers Study Group. 2015. The significance of *Lactobacillus crispatus* and *L. vaginalis* for vaginal health and the negative effect of recent sex: a cross-sectional descriptive study across groups of African women. *BMC Infectious Diseases* 15:115. DOI: 10.1186/s12879-015-0825-z.

Kuon RJ., Togawa R., Vomstein K., Weber M., Goeggl T., Strowitzki T., Markert UR., Zimmermann S., Daniel V., Dalpke AH., Toth B. 2017. Higher prevalence of colonization with *Gardnerella vaginalis* and gram-negative anaerobes in patients with recurrent miscarriage and elevated peripheral natural killer cells. *Journal of Reproductive Immunology* 120:15–19. DOI: 10.1016/j.jri.2017.03.001.

Leitich H., Bodner-Adler B., Brumbauer M., Kaider A., Egarter C., Husslein P. 2003. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. *American Journal of Obstetrics and Gynecology* 189:139–147. DOI: 10.1067/mob.2003.339.

Leitich H., Kiss H. 2007. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. *Best Practice and Research: Clinical Obstetrics and Gynaecology* 21:375–390. DOI: 10.1016/j.bpobgyn.2006.12.005.

Machado A., Castro J., Cereija T., Almeida C., Cerca N. 2015. Diagnosis of bacterial vaginosis by a new multiplex peptide nucleic acid fluorescence in situ hybridization method. *PeerJ* 3:e780. DOI: 10.7717/peerj.780.

Menard JP., Fenollar F., Henry M., Bretelle F., Raoult D. 2008. Molecular quantification of *Gardnerella vaginalis* and *Atopobium vaginae* loads to predict bacterial vaginosis. *Clinical Infectious Diseases* 47:33–43. DOI: 10.1086/588661.

Nelson DB., Hanlon A., Nachamkin I., Haggerty C., Mastrogiannis DS., Liu C., Fredricks DN. 2014. Early pregnancy changes in bacterial vaginosis-associated bacteria and preterm delivery. *Paediatric and Perinatal Epidemiology* 28:88–96. DOI: 10.1111/ppe.12106.

Nelson DB., Hanlon AL., Wu G., Liu C., Fredricks DN. 2015. First trimester levels of BV-associated bacteria and risk of miscarriage among women early in pregnancy. *Maternal and
Nugent RP., Krohn MA., Hillier SL. 1991. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. *Journal of Clinical Microbiology* 29:297–301.

Pararas MV., Skevaki CL., Kafetzis DA. 2006. Preterm birth due to maternal infection: causative pathogens and modes of prevention. *European Journal of Clinical Microbiology and Infectious Diseases* 25:562–569. DOI: 10.1007/s10096-006-0190-3.

Pépin J., Deslandes S., Giroux G., Sobéla F., Khonde N., Diakité S., Demeule S., Labbé AC., Carrier N., Frost E. 2011. The complex vaginal flora of West African women with bacterial vaginosis. *PloS One* 6:e25082. DOI: 10.1371/journal.pone.0025082.

Schellenberg JJ., Paramel Jayaparakash T., Withana Gamage N., Patterson MH., Vaneechoutte M., Hill JE. 2016. *Gardnerella vaginalis* subgroups defined by cpn60 sequencing and sialidase activity in isolates from Canada, Belgium and Kenya. *PLoS One* 11:e0146510. DOI: 10.1371/journal.pone.0146510.

Schwebke JR., Flynn MS., Rivers CA. 2014. Prevalence of *Gardnerella vaginalis* among women with *Lactobacillus*-predominant vaginal flora. *Sexually Transmitted Infections* 90:61–63. DOI: 10.1136/sextrans-2013-051232.

Silva D., Henriques A., Cereija T., Martinez-de-Oliveira J., Miranda M., Cerca N. 2014. Prevalence of *Gardnerella vaginalis* and *Atopobium vaginae* in Portuguese women and association with risk factors for bacterial vaginosis. *International Journal of Gynaecology and Obstetrics* 124:178–179. DOI: 10.1016/j.ijgo.2013.08.008.

Sobel JD. 1997. Current Concepts: Vaginitis. *The New England journal of medicine* 337:1896–1903. DOI: 10.1056/NEJM199712253372607.

Spiegel CA., Amsel R., Holmes KK. 1983. Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid. *Journal of Clinical Microbiology* 18:170–177.

Verhelst R., Verstraeten H., Claeys G., Verschraegen G., Delanghe J., Van Simaey L., De Ganck C., Temmerman M., Vaneechoutte M. 2004. Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between *Atopobium vaginae*, *Gardnerella vaginalis* and bacterial vaginosis. *BMC Microbiology* 4:16. DOI: 10.1186/1471-2180-4-16.

Yeoman CJ., Yildirim S., Thomas SM., Durkin AS., Torralba M., Sutton G., Buhay CJ., Ding...
Y., Dugan-Rocha SP., Muzny DM., Qin X., Gibbs RA., Leigh SR., Stumpf R., White BA., Highlander SK., Nelson KE., Wilson BA. 2010. Comparative genomics of *Gardnerella vaginalis* strains reveals substantial differences in metabolic and virulence potential. *PloS One* 5:e12411. DOI: 10.1371/journal.pone.0012411.
Table 1 (on next page)

Primers used in this study.

Primers used in this study.
| Target                        | Set | Sequence (5’ to 3’)                  | TM (°C) | Amplification region (Genebank) | Reference               |
|------------------------------|-----|--------------------------------------|---------|-------------------------------|-------------------------|
| *G. vaginalis* 16S rRNA      | FW1 | CTCTTGGAAACGGGTGGTAA                 | 60      | KP996686.1 (from 99 to 399)   | (Henriques et al., 2012) |
|                              | RV1 | TTGCTCCCAATCAAAAGCGGT                | 62      |                               |                         |
|                              | FW2 | AGCCTAGGTGGGCGGTACC                 | 59      | KP996686.1 (from 206 to 373)  | (Castro et al., 2017)   |
|                              | RV2 | TGAGTAATGCGTGACCAACC                | 55      |                               |                         |
| *S. epidermidis* aap         | FW  | GCACCAGCTGTGGTTGTACC                | 59      | CP020463.1 (from 110863 to 111053) | (França et al., 2012)   |
|                              | RV  | GCATGCCTGCTGATAGTTCA                | 60      |                               |                         |

1 Notes.
2 TM, melting temperature; FW, forward; RV, reverse.
3
Table 2 (on next page)

Characteristics of the studied population

Characteristics of the studied population \((n = 206)\).
| Variables                        | %     |
|---------------------------------|-------|
| **Sociodemographic**            |       |
| Age (mean ±SD, years)           | 30.00 ± 5.16 |
| < 30 years                      | 41.75 |
| ≥ 30 years                      | 58.25 |
| **Educational level**           |       |
| ≤ Basic                         | 29.13 |
| Secondary                       | 35.44 |
| ≥ University                    | 35.44 |
| **Medical**                     |       |
| Previous BV                     | 7.77  |
| History of chronic disease      | 14.56 |
| **Reproductive**                |       |
| Previous delivery               | 41.75 |
| Previous preterm delivery       | 6.80  |
| Pregnancy trimester             |       |
| First                           | 11.65 |
| Second                          | 16.50 |
| Third                           | 71.84 |
| **Behavioral**                  |       |
| Tobacco consumption             | 12.62 |
| Use of intimate hygiene products| 28.64 |
| Vitamin supplementation         | 86.41 |

**Notes.**

1 SD, standard deviation; BV, bacterial vaginosis.
2 Values are given as mean ± SD or percentage (%).
Table 3 (on next page)

Characterization of women with or without BV

Sociodemographic, medical, reproductive, behavioral and microbiological variables among women with or without BV.
| Variables                      | BV positive (n = 8) | BV negative (n = 198) | p value | OR   | 95% CI        |
|-------------------------------|---------------------|-----------------------|---------|------|---------------|
| **Sociodemographic**          |                     |                       |         |      |               |
| Age (mean ± SD, years)        | 32.00 ± 3.16        | 29.91 ± 5.21          | 0.14    |      |               |
| < 30 years                    | 1                   | 85                    | 0.19    | 0.02 | 1.57          |
| ≥ 30 years                    | 7                   | 113                   | 5.27    | 0.64 | 43.63         |
| **Educational level**         |                     |                       | 0.97    |      |               |
| ≤ Basic                       | 2                   | 58                    | 0.81    | 0.16 | 4.11          |
| Secondary                     | 3                   | 70                    | 1.10    | 0.26 | 4.73          |
| ≥ University                  | 3                   | 70                    | 1.10    | 0.26 | 4.73          |
| **Medical**                   |                     |                       |         |      |               |
| Previous BV                   | 2                   | 14                    | 0.12    | 4.38 | 0.81-23.75    |
| History of chronic disease    | 3                   | 27                    | 0.09    | 3.80 | 0.86-16.83    |
| **Reproductive**              |                     |                       |         |      |               |
| Previous delivery             | 4                   | 82                    | 0.72    | 1.42 | 0.34-5.82     |
| Previous preterm delivery     | 2                   | 12                    | 0.09    | 5.17 | 0.94-28.39    |
| Pregnancy trimester           | 0.27                |                       |         |      |               |
| First                         | 2                   | 22                    | 2.67    | 0.51 | 14.04         |
| Second                        | 0                   | 34                    | 0.28    | 0.02 | 4.98          |
| Third                         | 6                   | 142                   | 1.18    | 0.23 | 6.04          |
| **Behavioral**                |                     |                       |         |      |               |
| Tobacco consumption           | 0                   | 26                    | 0.60    | 0.38 | 0.02-6.84     |
| Use of intimate hygiene       | 4                   | 55                    | 0.23    | 2.60 | 0.63-10.76    |
| Vitamin supplementation       | 7                   | 171                   | 1.00    | 1.11 | 0.13-9.35     |
| **Microbiological**           |                     |                       |         |      |               |
| G. vaginalis presence         | 8                   | 131                   | 0.06    | 8.73 | 0.50-153.60   |

**Notes.**

1. BV, bacterial vaginosis; OR, odds ratio; CI, confidence interval; SD, standard deviation.
2. Values are given as mean ± SD or number.
Table 4 (on next page)

Characterization of women with or without vaginal colonization by G. vaginalis

Sociodemographic, medical, reproductive, behavioral and microbiological variables among women with or without G. vaginalis colonization.
| Variables               | GV positive (n=139) | GV negative (n=67) | p value | OR     | 95% CI     |
|-------------------------|---------------------|--------------------|---------|--------|------------|
| **Sociodemographic**    |                     |                    |         |        |            |
| Age (mean ± SD, years)  | 29.94 ± 5.35        | 30.12 ± 4.78       | 0.88    |        |            |
| < 30 years              | 59                  | 27                 | 1.09    | 0.60-1.98 |            |
| ≥ 30 years              | 80                  | 40                 | 0.92    | 0.51-1.66 |            |
| **Educational level**   |                     |                    | 0.02    |        |            |
| ≤ Basic                 | 49                  | 11                 | 2.77    | 1.33-5.78 |            |
| Secondary               | 47                  | 26                 | 0.81    | 0.44-1.47 |            |
| ≥ University            | 43                  | 30                 | 0.55    | 0.30-1.01 |            |
| **Medical**             |                     |                    |         |        |            |
| Previous BV             | 13                  | 3                  | 0.28    | 2.20   | 0.61-8.01 |
| History of chronic disease | 24             | 6                  | 0.14    | 2.12   | 0.82-5.47 |
| **Reproductive**        |                     |                    |         |        |            |
| Previous delivery       | 62                  | 24                 | 0.29    | 1.44   | 0.79-2.63 |
| Previous preterm delivery | 9               | 5                  | 0.77    | 0.86   | 0.28-2.67 |
| Pregnancy trimester     |                     |                    | <0.01   |        |            |
| First                   | 17                  | 7                  | 1.19    | 0.47-3.04 |            |
| Second                  | 31                  | 3                  | 6.12    | 1.80-20.85 |            |
| Third                   | 91                  | 57                 | 0.33    | 0.16-0.71 |            |
| **Behavioral**          |                     |                    |         |        |            |
| Tobacco consumption     | 22                  | 4                  | 0.07    | 2.96   | 0.98-8.98 |
| Use of intimate hygiene products | 45       | 14                 | 0.10    | 1.81   | 0.91-3.61 |
| Vitamin supplementation | 124                 | 54                 | 0.13    | 1.99   | 0.89-4.47 |
| **Microbiological**     |                     |                    | 0.02    |        |            |
| Normal flora            | 94                  | 56                 | 0.41    | 0.20-0.86 |            |
| Intermediate flora      | 37                  | 11                 | 1.85    | 0.87-3.90 |            |
| BV flora                | 8                   | 0                  | 8.73    | 0.50-153.60 |            |

Notes.
GV, *Gardnerella* vaginalis; OR, odds ratio; CI, confidence interval; SD, standard deviation; BV, bacterial vaginosis.

Values are given as mean ± SD or number.